Drug intelligence / Profile preview

KLH-DC vaccine

Development stage: Preclinical
Lead developer: Stellar Biotechnologies
Modality: Cell Therapies, Vaccines & Immunotherapeutics
Administration: Subcutaneous, Intradermal, Intramuscular, Intranodal, Intranasal

Overview

KLH-DC vaccine is a dendritic cell-based vaccine developed for veterinary use, specifically in the treatment of canine malignant melanoma. It consists of dendritic cells pulsed with Keyhole Limpet Hemocyanin (KLH) to induce immune responses. In studies, vaccination with KLH-DC has been shown to elicit delayed-type hypersensitivity (DTH) responses against KLH, indicating the induction of T cell-mediated immunity.

Other names: KLH-DC

Beyond the preview

Go deeper on KLH-DC vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KLH-DC vaccine.

Explore the full profile